Evidence map›Paper›PMID 32083210›Full record

ArticleHeliyon2020

Somatic mutation landscape reveals differential variability of cell-of-origin for primary liver cancer.

Kyungsik Ha, Masashi Fujita, Rosa Karlić, Sungmin Yang, Ruidong Xue, Chong Zhang, Fan Bai, Ning Zhang, Yujin Hoshida, Paz Polak and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 5 countries.

Kyungsik HaBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul, 08826, South Korea.
Masashi FujitaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, 230-0045, Japan.
Rosa KarlićBioinformatics Group, Department of Molecular Biology, Division of Biology, Faculty of Science, University of Zagreb, Horvatovac 102a, 10000, Zagreb, Croatia.
Sungmin YangBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul, 08826, South Korea.
Ruidong XueBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing, 100871, China.
Chong ZhangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing, 100871, China.
Fan BaiBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing, 100871, China.
Ning ZhangBiomedical Pioneering Innovation Center (BIOPIC) and Translational Cancer Research Center, School of Life Sciences, First Hospital, Peking University, Beijing, 100871, China.
Yujin HoshidaLiver Tumor Translational Research Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA.
Paz PolakDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., NY, 10029, USA.
Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, 230-0045, Japan.
Hong-Gee KimBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul, 08826, South Korea.
Hwajin LeeBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul, 08826, South Korea.
Peking University · CNSeoul National University · KRRIKEN Center for Integrative Medical Sciences · JPIcahn School of Medicine at Mount Sinai · USThe University of Texas Southwestern Medical Center · USUniversity of Zagreb · HR

Funding

Reverse-engineering precision liver cancer chemopreventionR01CA233794 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN · 2019 to 2023
$3.5M
Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
NCI NIH HHS R01 CA233794NIDDK NIH HHS R01 DK099558
6 · The paper itself

Abstract

Primary liver tissue cancer types are renowned to display a consistent increase in global disease burden and mortality, thus needing more effective diagnostics and treatments. Yet, integrative research efforts to identify cell-of-origin for these cancers by utilizing human specimen data were poorly established. To this end, we analyzed previously published whole-genome sequencing data for 384 tumor and progenitor tissues along with 423 publicly available normal tissue epigenomic features and single cell RNA-seq data from human livers to assess correlation patterns and extended this information to conduct

Indexed as

Biocomputational methodBioinformatics-based prediction of cell-of-originCancer researchGene mutationGenome and single-cell RNA-Seq dataGenomicsIntegration of epigenomePrimary liver cancersSystems biology

Identifiers

PMID32083210
PMCPMC7016380
OpenAlexW3005550024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.